Quote this publication Share Print


Opinions on drugs - Posted on Sep 09 2014

Reason for request



Clinical Benefit


The AB of VONCENTO is :

- substantial in the indication: “von Willebrand disease (VWD): Treatment of bleeding episodes or prevention and treatment of surgical bleeding in patients with von Willebrand disease, when desmopressin (DDAVP) treatment alone is ineffective or contraindicated.”


- insufficient in the indication “Haemophilia A (congenital factor VIII deficiency) : Prophylaxis and treatment of bleeding in patients with haemophilia A.

Clinical Added Value

no clinical added value

VONCENTO does not provide any improvement in actual benefit (IAB V, non-existent) in the current management of von Willebrand disease.

Not applicable

Haemophilia A : Not applicable